Lysosomal Protease Cathepsin D is a Prognostic Marker in Endometrial Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Jun 1

PMID 8664123

Citations 2

Authors

A Losch

P Kohlberger

G Gitsch

A Kaider

G Breitenecker

C Kainz

Affiliations

Soon will be listed here.

Abstract

The present study investigates the prognostic value of immunohistochemically detected cathepsin D expression in endometrial adenocarcinoma. Patients with surgically treated endometrial adenocarcinoma FIGO stages I-III and consecutive irradiation therapy were included in the study. When we performed immunohistochemistry to detect cathepsin D in 115 tissue specimens 35 cases showed a positive reaction. In the univariate analysis cathepsin D expression showed significant prognostic value for overall survival (P-value = 0.007). In the multivariate analysis with established prognostic parameters (stage, grade) we found an independent prognostic value for cathepsin D (P-value = 0.002, relative risk = 3.8, 95% confidence interval 1.4 - 10.0). Immunohistochemical detection of cathepsin D could aid in predicting prognosis and planning therapy for patients with endometrial adenocarcinoma.

Citing Articles

Hub Gene and Its Key Effects on Diffuse Large B-Cell Lymphoma by Weighted Gene Coexpression Network Analysis.

Ma C, Li H Biomed Res Int. 2021; 2021:8127145.

PMID: 34873574 PMC: 8643236. DOI: 10.1155/2021/8127145.

The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian Cancer.

Pranjol M, Gutowski N, Hannemann M, Whatmore J Biomolecules. 2015; 5(4):3260-79.

PMID: 26610586 PMC: 4693277. DOI: 10.3390/biom5043260.

References

Greco N, Tenner Jr T, Tandon N, Jamieson G . PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change. Blood. 1990; 75(10):1989-90. View

ROCHEFORT H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I . Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem. 1989; 34(1-6):177-82. DOI: 10.1016/0022-4731(89)90080-0. View

ROCHEFORT H . Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol. 1992; 31(2):125-30. DOI: 10.3109/02841869209088891. View

Creasman W . Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol. 1993; 5(1):80-3. View

Creasman W . Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993; 71(4 Suppl):1467-70. DOI: 10.1002/cncr.2820710411. View

Nazeer T, Church K, Amato C, Ambros R, Rosano T, MALFETANO J . Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumor aggressiveness. Mod Pathol. 1994; 7(4):469-74. View

Cardiff R . Cathepsin D and breast cancer: useful?. Hum Pathol. 1994; 25(9):847-8. DOI: 10.1016/0046-8177(94)90001-9. View

Castiglioni T, Merino M, Elsner B, Lah T, Sloane B, Emmert-Buck M . Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol. 1994; 25(9):857-62. DOI: 10.1016/0046-8177(94)90003-5. View

Roger P, Montcourrier P, Maudelonde T, Brouillet J, Pages A, Laffargue F . Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol. 1994; 25(9):863-71. DOI: 10.1016/0046-8177(94)90004-3. View

10.

Ng A, REAGAN J . Incidence and prognosis of endometrial carcinoma by histologic grade and extent. Obstet Gynecol. 1970; 35(3):437-43. View

11.

Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R . Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982; 6(2):93-108. DOI: 10.1097/00000478-198203000-00002. View

12.

CHRISTOPHERSON W, Connelly P, Alberhasky R . Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer. 1983; 51(9):1705-9. DOI: 10.1002/1097-0142(19830501)51:9<1705::aid-cncr2820510924>3.0.co;2-c. View

13.

Baltzer J, Lohe K, Kuerzl R, Scheer K, Zander J . Prognostic criteria in patients with endometrial cancer. Arch Gynecol. 1983; 234(2):121-9. DOI: 10.1007/BF00207684. View

14.

ROCHEFORT H, Capony F, Garcia M, Cavailles V, Freiss G, Chambon M . Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis?. J Cell Biochem. 1987; 35(1):17-29. DOI: 10.1002/jcb.240350103. View

15.

Thorpe S, ROCHEFORT H, Garcia M, Freiss G, Christensen I, Khalaf S . Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989; 49(21):6008-14. View

16.

Spyratos F, Maudelonde T, Brouillet J, Brunet M, Defrenne A, Andrieu C . Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989; 2(8672):1115-8. DOI: 10.1016/s0140-6736(89)91487-6. View

17.

Maudelonde T, Martinez P, Brouillet J, Laffargue F, Pages A, ROCHEFORT H . Cathepsin-D in human endometrium: induction by progesterone and potential value as a tumor marker. J Clin Endocrinol Metab. 1990; 70(1):115-21. DOI: 10.1210/jcem-70-1-115. View

18.

Henry J, McCarthy A, Angus B, Westley B, May F, Nicholson S . Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990; 65(2):265-71. DOI: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1. View

19.

Tandon A, Clark G, Chamness G, Chirgwin J, McGuire W . Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990; 322(5):297-302. DOI: 10.1056/NEJM199002013220504. View

20.

Touitou I, Cavailles V, Garcia M, Defrenne A, ROCHEFORT H . Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Mol Cell Endocrinol. 1989; 66(2):231-8. DOI: 10.1016/0303-7207(89)90035-x. View